Every investor in Savara Inc. (NASDAQ:SVRA) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are private equity firms with 41% ownership.
TipRanks on MSN
Savara price target raised to $10 from $8 at HC Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Savara (SVRA) to $10 from $8 and keeps a Buy rating on the shares. The ...
Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024. Savara said it had enough cash to fund ...
TipRanks on MSN
Savara resubmits Molbreevi BLA to the FDA
Savara (SVRA) announced that it has resubmitted the Molbreevi BLA to the FDA, with Fujifilm as the drug substance manufacturer. The Molbreevi BLA ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of ...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols ...
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc. View source version ...
In response to favorable analyst coverage, shares of Savara (NASDAQ: SVRA), a clinical-stage biotech focused on rare lung diseases, soared 23% as of 12:10 p.m. EDT on Friday. Savara's investors can ...
The company didn't announce anything lately that would drive the stock forward, but its shares have been on a two-week rise. Its lead product candidate, molgramostim, is an inhaled ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback